Illumina Granted Registration in Russia for Clinical NGS Platform, Reagents
Illumina Granted Registration in Russia for Clinical NGS Platform, Reagents March 5, 2021 Illumina's NextSeq™ 550Dx next-generation sequencing (NGS) platform (pictured), associated reagent kits, and reagents for the company’s MiSeq™Dx have all been approved for use in Russia by the country’s medical device regulatory agency, Roszdravnadzor. [Illumina] Illumina said that its NextSeq 550Dx next-generation sequencing (NGS) platform, associated reagent kits, and reagents for the company’s MiSeq Dx have all been approved for use in Russia by the country’s medical device regulatory age...